DWP 213388
Alternative Names: DWP-213388; VIT-801Latest Information Update: 28 Jan 2025
At a glance
- Originator Daewoong Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic urticaria
- No development reported Rheumatoid arthritis; Systemic lupus erythematosus
- Discontinued Graft-versus-host disease; Psoriasis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in South Korea (PO)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in South Korea (PO)
- 05 Nov 2024 Daewoong Pharmaceutical withdraws prior to enrolment a phase I trial (In volunteers) due to licensing out (PO) (NCT05607589)